Background: This study examines a viable biodegradable three-dimensional fibroblast construct (3DFC) in a model of chronic heart failure. The viable fibroblasts, cultured on a vicryl mesh, secrete growth factors that stimulate angiogenesis. Methods: We ligated the left coronary artery of male Sprague-Dawley rats, implanted the 3DFC 3 weeks after myocardial infarction and obtained end point data 3 weeks later, that is, 6 weeks after myocardial infarction. Results: Implanting the 3DFC increases ( p < 0.05) myocardial blood flow twofold, microvessel formation (0.02 AE 0.01 vs. 0.07 AE 0.03 vessels/mm 2 ), and ventricular wall thickness (0.53 AE 0.02 to 1.02 AE 0.17 mm). The 3DFC shifts the passive pressure volume loop toward the pressure axis but does not alter left ventricular (LV) ejection fraction, systolic displacement, LV end-diastolic pressure/dimension, or LV cavity area. The 3DFC stimulates selected cytokine activation with a decrease in the proinflammatory cascade and increased total protein content stimulated by strained 3DFC in vitro. Conclusion: The 3DFC functions as a cell delivery device providing matrix support for resident cell survival and integration into the heart. The imbedded fibroblasts of the 3DFC release a complex blend of cardioactive cytokines promoting increases in microvessel density and anterior wall blood flow but does not improve ejection fraction or alter LV remodeling.
Introduction
C ell-based regenerative therapies have been explored recently as a treatment for myocardial infarction (MI) with mixed results. [1] [2] [3] Basic laboratory work shows dramatic increases in left ventricular (LV) function and survival.
Meanwhile, clinical trials demonstrate that intracoronary delivery of cells is safe, well tolerated, and results in modest improvements in LV function. [4] [5] [6] [7] [8] [9] [10] However, few studies focus on chronic heart failure (CHF), which affects nearly 5 million Americans with an estimated 500,000 new diagnoses annually. Fewer than 50% of patients found to have CHF survive more than 5 years. 11 Current clinical treatments focus on stabilizing CHF and preventing further deterioration; they neither stimulate angiogenesis nor regenerate myocytes or restore the lost functional and structural elements of the heart. [12] [13] [14] Studies evaluating cell-based therapies in CHF are generally nonconclusive showing 2%-3% increases in ejection fraction (EF) 10 including studies of skeletal myoblast injections in patients with ischemia undergoing coronary artery bypass grafting (CABG) that show no improvement in LV function. 15 While enthusiasm for cell-based therapy for heart failure remains high, the limited clinical beneficial effects may be because most transplanted cells do not survive when injected into the infarcted heart. [16] [17] [18] 45 Alternatively, new cell-based delivery techniques using bioengineered patches are evolving. [19] [20] [21] Previously, our laboratory 22 evaluated a biodegradable three-dimensional fibroblast construct (3DFC) composed of a matrix-embedded human newborn dermal fibroblasts cultured onto a vicryl mesh to produce a living, metabolically active tissue. The 3DFC secretes angiogenic growth factors, including hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) ( Table 4) , which have been shown to increase new blood vessel formation in vivo. [23] [24] [25] In this study, the 3DFC was evaluated in a rat CHF model. Echocardiography was employed for evaluation of EF, systolic displacement, and LV end systolic and diastolic diameter. We used solid-state micromanometers to obtain hemodynamic data. Structural improvements were verified using histological methods. Extensive investigation evaluated both the in vivo and in vitro angiogenic properties of the 3DFC. Lastly, the 3DFC's proinflammatory markers were evaluated in strained versus static culture conditions in vitro.
Materials and Methods

Experimental design and treatment groups
Normal adult male Sprague-Dawley rats underwent left coronary artery ligation and were randomized to sham or 3DFC placement 3 weeks after surgery with three treatment groups: Sham, CHF, and CHF þ 3DFC. The experiments were performed in an Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC)-accredited facility with approval from animal use committees of Southern Arizona Veterans Administration Health Care System (SAVAHCS) and the University of Arizona.
Coronary artery ligation experimental MI
The rat coronary artery ligation model is standard in our laboratory. 22, [26] [27] [28] [29] [30] [31] [32] Rats were anesthetized with ketamine and acepromazine, a left thoracotomy was performed, the heart expressed from the thorax, and a ligature was placed around the proximal left coronary artery. The rats were maintained on standard rat chow, water ad libitum, and pain medication postoperatively.
The 3DFC patch
The 3DFC is a cryopreserved human fibroblast, extracellular matrix, on a bioabsorbable scaffold 22, 33, 34 (Supplemental Fig. S1 , available online at www.liebertonline.com/ten). The fibroblast cells are tested for animal viruses, retroviruses, cell morphology, karology, isoenzymes, and tumorgenicity and free from viruses, retroviruses, endotoxins, and mycoplasma. The 3DFC was provided by Theregen, Inc., and is frozen (À758C AE 108C) in pieces 5Â7.5 cm with an average thickness of 200 micrometers. The 3DFC was thawed in phosphate buffered saline (348C-378C), handled gently by the edges to limit cellular damage, and applied to the heart within 60 min of being removed from its container (Supplemental Fig. S2A , available online at www.liebertonline.com/ ten). The 3DFC does not generate an immune response in previous work 22, [33] [34] [35] (Investigators' brochure ITT-101; Theregen), or in current clinical studies (data not published). The low immunogenicity of allogeneic fibroblasts may be because these fibroblasts show little induction of cluster of differentiation (CD)40 and human leukocyte antigen-DR (HLA-DR) in response to g-interferon. 35 
Hemodynamic measurements in vivo
Using standard techniques developed in our laboratory, rats were anesthetized with inactin (100 mg/kg intraperitoneal injection), placed on a specially equipped operating table with a heating pad, intubated, and placed on a rodent ventilator with a 2F solid state micromanometer tipped catheter with two pressure sensors (Millar Instruments, Inc.) inserted via the right femoral artery, with one sensor located in the left ventricle and another in the ascending aorta. The pressure sensor is equilibrated in 378C saline, and LV and aortic pressures/heart rate were recorded, digitized at a rate of 1000 Hz to calculate LV dP/dt and the time constant of LV relaxation or tau. 22, 26, [29] [30] [31] [32] 36 LV pressure-volume relationships in vitro
We measured LV pressure-volume (PV) relations with the heart arrested with potassium chloride, and a PE-90 catheter with telescoped PE-10 tubing inside, inserted into the LV via the aortic root. One end of the double-lumen LV catheter was connected to a volume infusion pump (Harvard Apparatus), whereas the other end was connected to a pressure transducer zeroed at the level of the heart. The right ventricle was partially incised to prevent loading on the left ventricle. The LV was filled (1.0 mL/min) to 60-100 mmHg and unfilled while pressure was recorded onto a physiologic recorder (Gould Electronics); ischemic time from euthanasia to the PV curves was limited to 10 min; the volume infused is a function of filling rate. 22, 27, 28 From the pressure-volume data recorded in vivo, the stiffness constants K 0 , K 1 , K 2 , K 3 , and K 4 are determined by methods described previously by our laboratory. 30 In brief, pairs of simultaneous pressure-volume points (15 pairs for each pressure interval) were obtained. The stiffness constants were calculated with the following analysis: the pressurevolume data are fitted to the exponential equation P ¼ P 0 e KV (pressure is assumed to be equal to P 0 when volume is zero). Thus, ln P ¼ ln P 0 þ KV, and when lnP was plotted versus V, K is the slope of this relation. The overall stiffness constant was K 0 (2.5-30 mmHg). K 1 (0-3 mmHg), K 2 (3-10 mmHg), K 3 (10-20 mmHg), and K 4 (20-30 mmHg) were derived.
Echocardiography
We performed closed chest transthoracic echocardiography using a Vingmed, Vivid 7 system echo machine (GE Ultrasound) with EchoPac (GE Ultrasound) programming software with a 10 MHz multiplane transducer with views in the parasternal short axis and long axis, to evaluate the anterior, lateral, antero-lateral, inferior, and posterior walls. Systolic displacement of the anterior wall and EF were obtained from 2D and M-mode measurements of myocardial wall thickness and LV dimensions. Systolic displacement is a measure of focal LV wall thickening; from the M mode through the anterior wall, the difference in the thickness between systole and diastole is the systolic displacement. This was used to quantify focal LV wall systolic function with particular reference to this study where we measure systolic displacement of the anterior infarcted wall.
22,32
Myocardial perfusion
We used neutron-activated microspheres (BioPal, Inc.) to measure myocardial blood flow. The isotopes were injected, and a tissue sample was obtained, and at a later time activated with the emitted radiation measured with high resolution detection equipment. 22, [37] [38] [39] Three separate isotopes 2 LANCASTER ET AL.
(lutetium, gold, and samarium) were injected: one at baseline before coronary ligation, one immediately after ligation at the time of the acute MI, and one at 6 weeks in separate groups of rats with CHF, and with CHF þ 3DFC. For each measurement 750,000 nonradioactive elementally labeled 15 mm microspheres (V ¼ 300 mL) from Biopal, Inc., were injected into the left ventricle transapically with a 1 cc syringe and 27-gauge needle. At the terminal study point, tissues were harvested, oven-dried, and collected for analysis. At the time of microsphere injection we performed a transthoracic echocardiogram to measure stroke volume and calculate cardiac output as stroke volumeÂheart rate. Assuming that 4% of the cardiac output perfuses the coronary arteries, 39 we know the total myocardial blood flow. The microspheres deposited in the anterior wall represent the percentage of blood flow down the left coronary artery to the anterior wall at each time point. 22 
Microvessel histopathology
Hearts were formalin fixed (10%) before paraffin embedding. Heat-induced epitope retrieval of 3-mm-thick sections was performed in citrate-based Diva buffer (pH 6.2) for 1 min at 1258C using a Decloaker pressure cooker (Biocare Medical). We used single immunohistochemical staining for antirabbit factor VIII (Dako) (1:1000) to perform histological analysis of microvessel density defined by light microscopy at 40Âmagnification. The number of cross-sectional vessels per field was counted by two people blinded to treatment, and average measurements from six different fields were recorded for each value. Knowing the area of the optical field, data were reported as number of vessels/mm 2 .
Fibroblast identification histopathology
Rodent heart samples were processed and embedded into paraffin for subsequent 5 mm sectioning. Vimentin antibody was purchased from Santa Cruz Biotechnology (cat# sc-32322) and used at a 1:100 dilution in blocking solution. Heat antigen retrieval using citrate buffer was applied before blocking incubation. Primary antibody was incubated overnight. An ABC system from Vector Laboratories was used to amplify the signal with subsequent peroxidase 3,3 0 -diaminobenzidine (DAB) treatment. Light methyl green was used as a background counterstain.
Trichrome staining
Cut sections were deparaffinized and incubated in potassium dichromate-hydrochloric acid solution, stained with acid fuchsin, fixed with phosphomolybdic acid solution, and stained with orange G. Lastly, sections were treated with aqueous acetic acid, aniline blue, and acetic acid; rinsed with EtOH; and dehydrated in absolute alcohol.
Left ventricle measurements
We injected 40 meq/mL potassium chloride into the right ventricle to arrest the heart in diastole. A bolus of 1 mL per 100 g of body weight was rapidly injected into the right ventricle, effecting arrest. Images of trichrome-stained heart sections were captured around the entire circumference of a mid-LV cross-sectional slice. Calibrated, scaled, individual images were stitched together using imaging processing software (Adobe Photoshop Elements). Measurements of each heart were taken using image analysis software (NIH Image J 1.39u), again calibrated from images with a standardized micrometer. The average of three measurements for each heart was taken to represent the wall thickness and LV cavity area value for each heart. Five animals were evaluated from each treatment group (CHF vs. CHFþ3DFC).
Biomechanical strain induced cytokine secretion
The 3DFC were attached to BioFlex Ò collagen-coated membranes using a waterproof adhesive and incubated in a medium containing 2% fetal bovine serum for 24 h. The   FIG. 1 . Trichrome-stained left ventricular (LV) sections of (A) chronic heart failure (CHF) versus (B) three-dimensional fibroblast-construct (3DFC)-treated CHF hearts. The 3DFC increases LV wall thickness in treated versus untreated hearts.
FIG. 2.
Positive human-specific vimentin antibody staining demonstrates presence of the 3DFC's resident fibroblasts 3 weeks after implantation into a rat CHF model. Arrows illustrate positive human fibroblasts staining. Scale bar ¼ 100 mm.
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3DFC were equilaxially strained using a flexercell apparatus at 10% 1 Hz for 48 h to model an in vivo cardiac cycle. Conditioned medium samples were collected, and secreted peptides were identified and quantified via protein microarrays (RayBiotech Inc.). Fibroblast proliferation was assayed via dsDNA and total cellular protein concentration was assayed calorimetrically. Peptides were normalized in pg/mL per dsDNA concentration.
Statistical analysis
Data were expressed as mean AE standard error. For the physiologic and echocardiographic measurements, the Student t-test was used for single comparison of sham versus other study groups. Interactions were tested using two-way analysis of variance; intergroup differences were evaluated using the Student-Newman-Keuls test for statistical significance ( p 0.05). Pressure-volume relations were evaluated using multiple linear and polynominal regression analysis. The correlation of statistical difference was based on the DurbinWatson statistic, F-statistic, p-value, and variance coefficients.
Results
In our laboratory the rat coronary artery ligation model results in about a 40%-50% operative mortality to produce large infarcts with LV end-diastolic pressures >20 mmHg. 30, 31 Supplemental Figure S2 shows the 3DFC before implantation (A), with the chest reopened in a rat with an infarcted dilated heart 3 weeks after left coronary artery ligation (B), and the 3DFC implanted on this infarcted heart 3 weeks after MI (C).
LV dimensions
Echocardiography and immunohistochemistry were employed to detect functional and structural improvements in CHF groups treated with 3DFC. In a rat model of CHF, classically, there is a decrease ( p < 0.05) in LV EF (75% AE 2% to 35% AE 3%) with CHF; placement of the 3DFC does not restore EF (35% AE 5%) at 6 weeks (Supplemental Fig. S3A , available online at www.liebertonline.com/ten). In addition, regional LV function, defined as systolic displacement of the infarcted anterior wall, does not increase with the 3DFC (Supplemental Fig. S3B , available online at www.liebert online.com/ten).
The LV end-systolic and end-diastolic diameters increase almost twofold ( p < 0.05) in CHF from 0.39 AE 0.03 to 0.66 AE 0.10 cm and from 0.64 AE 0.04 to 0.93 AE 0.05 cm in CHF, respectively (Supplemental Fig. S4A , B, available online at www.liebertonline.com/ten). Placement of the 3DFC in CHF rats does not change the end-systolic (0.77 AE 0.04 cm) or enddiastolic dimension (0.90 AE 0.04 cm). Histological assessment reveals an increase in anterior wall thickness (Supplemental Fig. S5 , available online at www.liebertonline.com/ten, and Fig. 1 ) with implantation of the 3DFC from 0.53 þ 0.02 to 1.02 þ 0.17 mm (Fig. 1 A, B) but does not decrease LV cavity area (37.89 þ 3.72 to 38.46 þ 5.17 mm 2 ). Human-specific vimentin staining demonstrated resident fibroblasts from the 3DFC were present within the epicardial section of LV 3 weeks after implantation (Fig. 2) .
LV hemodynamics
Solid-state micromanometer catheters were placed in the LV and ascending aorta to evaluate LV hemodynamic changes. These data show what we and other laboratories have shown: rats with CHF, 6 weeks after left coronary artery ligation with a threefold increase in LV end diastolic pressure, a 23% reduction in LV systolic blood pressure, a 22% reduction in mean arterial blood pressure, a 36% reduction in positive LV dP/dt, a 50% reduction in negative LV dP/dt, a 40% decrease in peak developed pressure, and a 60% increase in tau ( p < 0.05), the time constant of LV relaxation (Table 1) . Implanting the 3DFC does not significantly ( p < 0.05) change any hemodynamic parameters described above. There is an increase ( p < 0.05) in right 
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ventricular weight in the CHF rats (Table 2) . Thus, implanting the nonviable 3DFC has no effect on any hemodynamic parameter.
Pressure-volume loops
The PV relationship shows dilatation of the left ventricle in CHF; the 3DFC patch attenuates this dilatation with a shift to the left ( p < 0.05) toward the pressure axis (Fig. 3) . The overall LV chamber stiffness constant (K 0 ) decreases ( p < 0.05, Table 3 ) with CHF and returns toward sham with 3DFC (Table 3) .
Myocardial blood flow and vessel density
To determine if the 3DFC revascularized ischemic tissue, myocardial blood flow was evaluated using neutronactivated microspheres. Myocardial blood flow to the anterior infarcted wall decreases ( p < 0.05) in CHF; the 3DFC increases ( p < 0.05) myocardial blood flow in 3DFC-treated groups (Fig. 4) . Additionally, using immunohistochemistry, we evaluated microvessel density formation within the epicardial infarct and peri-infarct zones. Factor VIII staining (Fig. 5 ) reveled an increase ( p < 0.05) in microvessel density in groups treated with 3DFC (Fig. 6 ).
Strain induced cytokine stimulation
In an effort to understand the cytokine production of the 3DFC, selected angiogenic cytokines were measured (in vitro) in control (static) versus strained settings. Measurable amounts of monocyte chemoattractant protein-1 (MCP-1), HGF, interleukin-8 (IL-8), interferon-g, tumor necrosis factora, Angiogenin, VEGF, IL-1a, bFGF, Leptin, IL-1b, IL-4, IL-6, platelet-derived growth factor-BB, placental growth factor, and epidermal growth factor (EGF) were detected in conditioned medium samples from both control and strained 3DFC. Strain significantly ( p < 0.05) decreased extracellular concentrations of interferon-g, tumor necrosis factor-a, IL-1a, IL-1b, IL-4, and EGF. No appreciable angiopoietin-2 (Ang-2), heparin-binding EGF-like growth factor, IL-10, or IL-13 was detected in any samples (Table 4 ). In addition, equilbiaxial strain showed no significant ( p < 0.05) change in dsDNA concentration; however, total protein content was significantly ( p < 0.05) elevated with strain 2.32 AE 0.3 versus 3.44 AE 0.3 mg/mL.
Discussion
Our work demonstrates that implanting a viable fibroblast matrix patch in rats with CHF increases LV wall thickness and induces angiogenesis with a resultant increase in myocardial blood flow in the area of previous infarction. In addition, the 3DFC improves passive filling of the LV but does not contribute to improvement in EF or attenuate LV remodeling. Although the mechanisms responsible for the increase in myocardial blood flow and capillary density are not clear, we do show that 3DFC induces selective paracrine activation in vitro that may explain part of its benefit.
Previous work by our laboratory shows that when 3DFC is implanted acutely after MI, the patch improves myocardial blood flow, LV function, and also partially reverses LV remodeling. 22 It is unclear why the 3DFC, when implanted in rats with CHF, does not restore LV function or reverse LV remodeling. Acute placement of the 3DFC results in significant revascularization and restored blood flow to potentially 05 as compared to 6-week CHF. @ p < 0.05 compared to sham. The 3DFC improves blood flow in the infarcted wall in rats with CHF. Sham, n ¼ 12; 6-week CHF, n ¼ 8; 6-week CHFþ3DFC, n ¼ 13.
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stunned myocardium, possibly preserving tissue viability. However, if the 3DFC is placed in CHF after infarct expansion and scar development has already occurred, although the 3DFC still induces angiogenesis, the adverse LV remodeling cannot be reversed, at least not in the 3-week time frame, that is effective in an acute MI.
22
Ex vivo pressure relationship versus in vivo analysis
The 3DFC treatment shifts the PV relationship to the left, toward the pressure axis; however, the 3DFC had no change on LV end systolic or diastolic diameter. To explain this contradiction, echocardiography data were collected in vivo, while PV loop data were collected ex vivo. To measure the PV relation ex vivo, hearts were arrested in diastole using KCL, while left ventricular end diastolic diameter (LVEDD) was measured in vivo while the heart may not have been completely relaxed due to incomplete diastole and/or the presence of pericardium, which is typically removed during ex vivo preparation.
Paracrine activation
The 3DFC is a viable construct composed of a matrix, embedded with human newborn dermal fibroblasts cultured in vitro onto a bio-absorbable mesh to produce a living, metabolically active tissue that secretes growth factors (Table  4) but engendering no immune response. 35 The fibroblasts proliferate across the mesh (Supplemental Fig. S1 ) and secrete human dermal collagen, fibronectin, and glycosaminoglycans, embedded in a self-produced dermal matrix. Although the mechanisms of action of cell-based therapy are not clear, most investigators believe that paracrine stimulation from the cells themselves may be responsible for the beneficial effects. Paracrine stimulation has been shown to result in cardioprotection of the cardiomyocytes at the cellular level. 40 The 3DFC releases a complex blend of cardioactive cytokines (Table 4) with well-documented roles in regulating ventricular function, blood flow, and vessel density. The functional dynamics of some cytokines are potentially stimulated by other active peptides as well as interpolated environmental conditions, as in the case with the peptide MCP-1 acting together with IL-8 to enhance the metastatic migration of mural cells toward endothelial cells, promoting both the maturation of new blood vessels and arteriogenesis. [41] [42] [43] In hyperemic flow conditions, but not at rest, MCP-1 and Leptin increase collateral blood flow. 43 We measured several potent angiogenic growth factors secreted from the 3DFC in high concentrations, including HGF, VEGF, angiogenin, and bFGF. The HGF induces powerful mitogenic activity on endothelial cells, and increases blood vessel number when introduced into infarcted canine myocardium. 23 VEGF and bFGF bind to cell-surface-expressed receptors equipped with tyrosine kinase activity leading to improvements in LV remolding and myocyte hypertrophy. 24 VEGF also increases functional improvement of postinfarcted hearts. 25 Interestingly, our data show that the imbedded fibroblasts of the 3DFC response to biomechanical strain results in an increase in total protein, which may be due to upregulation of intracellular proteins such as actin, or an increase in extracellular matrix proteins such as collagen, elastin, and fibronectin, providing structural support and a scaffolding for cellular migration aiding in cardiac growth. In addition, these data show that strain decreased the fibroblasts' secretion of proinflammatory molecules (Table 4) , and suggest the possibility that heart rate and force of contraction may modify the peptide secretory profile of 3DFC. Mechanotransduction of human fibroblasts in 3D constructs have been investigated by others and supports these findings. 44 This described paracrine effect does not occur with the nonviable 3DFC (data not shown) presumably because the nonviable 3DFC does not contain living fibroblasts. Previous work in rats and mice has shown that implanting LANCASTER ET AL.
the nonviable 3DFC does not improve myocardial blood flow or improve LV function. 22, 33, 34 Thus, the benefits from the 3DFC are due to more than just the physical presence and the restraining effects of the patch.
Using the 3DFC as a delivery system
Although this present report outlines the use of the 3DFC by itself, as treatment for CHF, the fibroblast patch could be used as an adjuvant delivery system for cell-based therapy. Because patients in heart failure present in the chronic phase of their disease, this could be an elective procedure where cells are harvested, grown in culture, seeded on the 3DFC, and reimplanted in the patient.
With direct cell injection into the heart, the majority of transplanted cells do not survive. [16] [17] [18] The lack of survival of these injected cells is related, in part, to an inadequate blood supply and inadequate matrix support for the new cells. The injected cells are fragile, resulting in cell aggregation due to lack of physical support for the cells to attach to the tissue extracellular matrix. This 3D scaffold offers a potential solution to the problem of an inadequate cellular support structure (Supplemental Fig. S1 ). In addition, Figure 7 demonstrates the integration of the 3DFC into the infarcted tissue and remnants of the vicryl mesh support structure 3 weeks after implantation.
Conclusion
We report induced angiogenesis, LV wall thickening, and improvements in myocardial blood flow as well as passive LV filling, without reversal of EF or LV remodeling using the viable 3DFC implanted in rats with ischemia-induced CHF. Our concept is that the 3DFC provides a support structure that allows cells to grow into the damaged heart and create new blood vessel growth, resulting in increased myocardial blood flow. In addition, treatment with the 3DFC increases ventricular wall thickness. With the limited success of current approaches of direct cell injection into the heart, the FIG. 7. Trichrome-stained LV cross section of a 3DFC-treated CHF heart. Higher magnification image inset highlighted in red; green arrows indicate remnants of vicryl mesh, yellow arrows indicate collagen fibers, and red asterisks indicate microvasculature. Within 3 weeks, the 3DFC vicryl mesh fibers have incorporation into the anterior wall. Cytokine, chemokine, and growth factor stimulation of angiogenic and inflammatory markers in static (control) versus strained 3DFC patches in vivo over 48 h (10% 1 Hz). Expression in pg cytokine/mg DNA, n ¼ 3. Adjusted for 2% fetal bovine serum media. a p < 0.05 versus control.
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3DFC represents a potentially new approach to cell-based therapy for CHF. The advantage of using the 3DFC is that it is an off-the-shelf product, does not generate an immune response, and can be delivered with a minimally invasive approach in patients. While we have used the 3DFC alone, this matrix patch could be viewed as a delivery system for cell-based therapy for heart failure where specific cells could be seeded on the 3DFC before implantation on the heart.
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